{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:58:33Z","timestamp":1772265513549,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>(1) Background and rationale: To validate the reported therapeutic coverage, a lymphatic filariasis post-mass drug administration (MDA) campaign survey was conducted in the Lukonga health zone from 10 June to 15 July 2023. (2) Materials and methods: This was a descriptive, cross-sectional study conducted at the community level in 30 villages in the Lukonga health zone from 10 June to 15 July 2023. The study population included all individuals from the visited communities. The study variables included age, sex, drug use (ivermectin + albendazole), adverse events, and adherence to MDA guidelines for supervised drug use. Questionnaires were administered on Android phones using the SurveyCTO platform. Stata version 17 was used for data analysis. (3) Results: Of the 1092 respondents, 54.8% were female and one-third were between the ages of 5 and 14. Two-thirds of the households surveyed, or 64%, had more than six people living in them, and 1031 individuals, or 94%, reported being present during the community mass drug distribution. Notably, 678 individuals, or 66%, reported taking the drugs offered, and 66.4% of those who took the drugs reported doing so in the presence of drug distributors. Thus, the survey coverage was 65.7% [95% CI: 62.9\u201368.7]. The results of this study show that the survey coverage was above the 65% threshold recommended by the WHO but below the 82.3% reported by the Lukonga health zone. The main reason for non-compliance was a fear of ivermectin-related side effects (47%). Supervised or directly observed treatment was not adhered to (66.4%). (4) Discussion and conclusions: Key challenges to further increase treatment coverage include assessing data quality, building capacity, motivating drug distributors, improving data reporting tools, proper recording by drug distributors, and accurate reporting on non-residents who take the drugs during the MDA. In addition, harmonization of the numerator for calculating drug coverage in the health zone is critical. It is imperative to provide the public with explicit information regarding the objective of drug distribution and the probable adverse effects.<\/jats:p>","DOI":"10.3390\/tropicalmed9070156","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T11:30:55Z","timestamp":1720697455000},"page":"156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Mass Drug Administration Coverage for Lymphatic Filariasis in the Lukonga Health Zone in 2022"],"prefix":"10.3390","volume":"9","author":[{"given":"Patrick N.","family":"Ntumba","sequence":"first","affiliation":[{"name":"Kinshasa School of Public Health, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3828-6214","authenticated-orcid":false,"given":"Pierre Z.","family":"Akilimali","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Kinshasa School of Public Health, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo"},{"name":"Patrick Kayembe Research Center, Kinshasa School of Public Health, University of Kinshasa, Kinshasa P.O. Box 11850, Democratic Republic of the Congo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"ref_1","unstructured":"(2024, March 18). Global Programme to Eliminate Lymphatic Filariasis: Progress Report. Available online: https:\/\/www.who.int\/publications-detail-redirect\/who-wer9641-497-508."},{"key":"ref_2","unstructured":"(2024, March 18). Filariose Lymphatique. Available online: https:\/\/www.who.int\/fr\/news-room\/fact-sheets\/detail\/lymphatic-filariasis."},{"key":"ref_3","unstructured":"(2024, March 18). WHO EMRO|Journ\u00e9e Mondiale de la Sant\u00e9 2014|Journ\u00e9e Mondiale de la Sant\u00e9\u201d. World Health Organization\u2014Regional Office for the Eastern Mediterranean. Available online: https:\/\/www.emro.who.int\/fr\/world-health-days\/world-health-day-2014\/index.html."},{"key":"ref_4","unstructured":"(2024, January 06). Weekly Epidemiological Record (WER), 4 October 2019, Vol. 94, No. 41 (pp. 457\u2013472) [EN\/FR]. World Relief Web. 11 October 2019. Available online: https:\/\/reliefweb.int\/report\/world\/weekly-epidemiological-record-wer-4-october-2019-vol-94-no-41-pp-457-472-enfr."},{"key":"ref_5","unstructured":"(2024, March 18). Suivi et \u00c9valuation \u00c9pid\u00e9miologique du Traitement M\u00e9dicamenteux de Masse Dans le Cadre du Programme Mondial Pour L\u2019\u00e9limination de la Filariose Lymphatique: Manuel \u00e0 L\u2019intention des Programmes Nationaux D\u2019\u00e9limination. Available online: https:\/\/www.who.int\/fr\/publications-detail\/9789241501484."},{"key":"ref_6","unstructured":"World Health Organization (2023, September 18). Coverage Surveys for Preventive Chemotherapy: Guidelines for Implementation. Available online: https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fmectizan.org%2Fwp-content%2Fuploads%2F2018%2F06%2FCoverage-Evaluation-Guidelines-Final-Draft_DEC-2016_clean.docx&wdOrigin=BROWSELINK."},{"key":"ref_7","unstructured":"(2024, March 18). Chimiopr\u00e9vention des Helminthiases Chez L\u2019homme\u2014Utilisation Coordonn\u00e9e des M\u00e9dicaments Anthelminthiques Pour les Interventions de Lutte. Available online: https:\/\/www.who.int\/fr\/publications-detail\/9241547103."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Babu, G., Olsen, J., Jana, S., Nandy, S., Farid, M. (2010). Evaluation of Immunization Cards and Parental Recall Against Gold Standard for Evaluating Immunization Coverage. Internet J. Epidemiol., 9, Available online: https:\/\/ispub.com\/IJE\/9\/2\/7407.","DOI":"10.5580\/111d"},{"key":"ref_9","first-page":"2","article-title":"\u00c9valuation de la couverture th\u00e9rapeutique de la campagne de traitement de masse contre la filariose lymphatique dans deux districts sanitaires au Burkina Faso","volume":"2","author":"Kabre","year":"2022","journal-title":"Med. Trop. Sante Int."},{"key":"ref_10","unstructured":"(2020). Plan National de Developpement Sanitaire 2016\u20132020: Vers la Couverture Sanitaire Universelle, Republique Democratique Du Congo Ministere de la Sante Publique. Available online: https:\/\/www.prb.org\/wp-content\/uploads\/2020\/06\/."},{"key":"ref_11","unstructured":"Minist\u00e8re du Plan et Suivi de la Mise en \u0152uvre de la R\u00e9volution de la Modernit\u00e9 (MPSMRM), Minist\u00e8re de la Sant\u00e9 Publique (MSP), and ICF International (2014). Enqu\u00eate D\u00e9mographique et de Sant\u00e9 en R\u00e9publique D\u00e9mocratique du Congo 2013\u20132014, ICF International."},{"key":"ref_12","unstructured":"(2011). OMS Programme Mondial D\u2019\u00e9limination de la Filariose Lymphatique\u2014Surveillance et \u00c9valuation \u00c9pid\u00e9miologique de L\u2019administration Massive de M\u00e9dicaments, Organisation Mondiale de la Sant\u00e9. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/363515\/WER9741-513-524-eng-fre.pdf?sequence=1&isAllowed=y."},{"key":"ref_13","unstructured":"(2024, March 23). Preventive Chemotherapy: Tools for Improving the Quality of Reported Data and Information: A Field Manual for Implementation. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789241516464."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.18203\/2394-6040.ijcmph20180754","article-title":"Evaluation of Mass Drug Administration Programme for Elimination of Lymphatic Filariasis in Bidar District, Karnataka","volume":"5","author":"Hoolageri","year":"2018","journal-title":"Int. J. Community Med. Public Health"},{"key":"ref_15","unstructured":"Akilimali, P.Z. (2023). ESP Kinshasa. Rapport d\u2019enqu\u00eate: Enqu\u00eates de couverture post traitement des MTN-CTP dans les coordinations Kasai Oriental, Kongo Central, Kwango, Maniema, Nord Ubangi et Sankuru. Available at the National Program for the Control of Neglected Tropical Diseases with Preventive Chemotherapy-DRC, Unpublished report."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Silumbwe, A., Zulu Jm Halwindi, H., Jacobs, C., Zgambo, J., Dambe, R., Chola, M., Chongwe, G., and Michelo, C. (2017). A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health, 17.","DOI":"10.1186\/s12889-017-4414-5"},{"key":"ref_17","first-page":"391","article-title":"A Study on Coverage Evaluation, Compliance and Awareness of Mass Drug Administration for Elimination of Lymphatic Filariasis in Osmanabad District","volume":"3","author":"Godale","year":"2012","journal-title":"Natl. J. Community Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.18203\/2394-6040.ijcmph20162241","article-title":"Evaluation of Mass Drug Administration Programme for Elimination of Lymphatic Filariasis in Nalgonda District, Telangana, India","volume":"3","author":"Jothula","year":"2016","journal-title":"Int. J. Community Med. Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14656566.6.2.179","article-title":"Treatment strategies underpinning the global programme to eliminate lymphatic filariasis","volume":"6","author":"Gyapong","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_20","first-page":"5","article-title":"Coverage Evaluation Survey of Mass Drug Administration for Lymphatic Filariasis in Purbabarddhaman District, West Bengal","volume":"17","author":"Paul","year":"2020","journal-title":"IOSR J. Dent. Med. Sci."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/9\/7\/156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:04Z","timestamp":1760109304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/9\/7\/156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["tropicalmed9070156"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed9070156","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}